Endocan Level in Patients With Erectile Dysfunction and Relationship With Tadalafil Treatment

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05109377

Enrollment

Registered

2021-11-05

Start date

2021-06-24

Completion date

2021-12-15

Last updated

2021-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Keywords

Endocan, Erectile dysfunction, Tadalafil

Brief summary

The investigators analyze the patients' endocan levels, IIEF scores, and hormon levels both before and after tadalafil (5 or 20mg) treatment. The investigators want to see erectile dysfunction severity and tadalafil treatment relations with endocen level.

Detailed description

The investigators will include at least 90 patients in study. Blood tests will taken before and after tadalafil treatment and will store at -80 celcius degree.

Interventions

DIAGNOSTIC_TESTEndocan

Endocan will measured before and after treatment

DRUGtadalafil

tadalafil

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

MALE

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

• Patients with erectile dysfuction

Exclusion criteria

* Psychogenic erectile dysfunction * Erectile dysfunction associated with hormonal disorders * Drug related erectile dysfunction

Design outcomes

Primary

Measure	Time frame	Description
Rates of IIEF Score	1 month	Levels of Endocan relationship with IIEF

Secondary

Measure	Time frame	Description
Levels of Endocan	1 month	Levels of Endocan with tadalafil treatment

Countries

Turkey (Türkiye)

Contacts

Primary ContactVeysel Bayburtluoğlu

bayburtluogluveysel@gmail.com+905530299981

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026